The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir) to cover its use…
News
BILIARY ATRESIA
NewsEased symptoms may predict success of second biliary atresia surgery: Study
Infants with biliary atresia who show some signs of recovery after undergoing standard Kasai surgery — a procedure to restore the flow of the…
Nearly one in five people with chronic hepatitis B who were given add-on treatment with GlaxoSmithKline (GSK)’s bepirovirsen in two global clinical trials…
CHOLANGITIS
NewsLivdelzi lowers liver damage marker across PBC trials, data show
Gilead Sciences‘ Livdelzi (seladelpar) effectively reduces blood levels of alkaline phosphatase (ALP), a key marker of liver damage, in most people with primary…
CHOLESTASIS
NewsBlood levels of gut protein may be marker of ICP, study finds
Blood levels of xenin-25, a small protein (peptide) produced in the gut, may serve as a biomarker to help diagnose intrahepatic cholestasis of pregnancy,…
FATTY LIVER DISEASE
NewsWegovy MASH benefits seen across patient groups in trial analyses
Treatment with Wegovy (semaglutide) showed a consistent safety and efficacy profile across a range of patient subgroups with metabolic dysfunction-associated steatohepatitis (MASH), a serious…
ALAGILLE SYNDROME
NewsLivmarli helps clear fatty skin growths in Alagille kids, study finds
Treatment with Livmarli (maralixibat) can reduce cholesterol levels and help clear fatty skin growths called xanthomas in children with Alagille syndrome, according to…
PBGENE-HBV, Precision Biosciences’ experimental gene-editing therapy for chronic hepatitis B, showed early evidence of eliminating and inactivating hepatitis B viral DNA as designed,…
CHOLANGITIS
NewsOral ABI-6250 may move into Phase 2 clinical testing for PBC and PSC
Assembly Biosciences plans to develop its investigational oral treatment, ABI-6250, for people with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hepcludex (bulevirtide-gmod), in development by Gilead Sciences, for treating adults with…
Recent Posts
- Key European panel backs expansion of Maviret to treat acute hepatitis C
- Eased symptoms may predict success of second biliary atresia surgery: Study
- Add-on treatment brings functional cure to hepatitis B patients
- Livdelzi lowers liver damage marker across PBC trials, data show
- There are ways to manage chronic pain when you’re living with MASH